Share

Profile & Fundamentals

Hims & Hers Health Profile & Fundamentals

Name: Hims & Hers Health financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Company profile record

Hims Hers Health Inc

Common Stock · Health Care · Health Care Services

Official website

Company

Company / asset: Hims Hers Health Inc
Security type: Common Stock
Sector: Health Care
Industry: Health Care Services
HQ: 🇺🇸 United States
Head office: 2269 Chestnut Street, San Francisco, CA, United States, 94123

Leadership & scale

Chief executive: Mr. Andrew Dudum
CEO year born: 1988
Full-time employees: 2.4K
Fiscal year end: December
IPO date: 2019-09-13

Fundamentals snapshot

Updated 2026-09-13

Market Cap: USD 6.5B
P/E: --
Revenue (Q2 26): USD 753.2M
Profit (Q2 26): USD -86.3M
Dividend Yield: --
Revenue (FY 25): USD 2.3B
Shares in public float: 213.7M
Insider ownership: 4.97%

Reporting & identifiers

Symbol: HIMS.NYSE
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US4330001060
Asset ID: equity_66030d24-c4db-5de4-b6cd-c0c5afaa1703

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc26,337,158 shares · 11.29% · Reported 2026-03-31
Vanguard Portfolio Management, LLC10,183,813 shares · 4.36% · Reported 2026-03-31
Vanguard Capital Management, LLC9,339,711 shares · 4.00% · Reported 2026-03-31
Morgan Stanley - Brokerage Accounts8,889,088 shares · 3.81% · Reported 2026-03-31
State Street Corp7,460,023 shares · 3.20% · Reported 2026-03-31
Defiance ETFs, LLC7,424,258 shares · 3.18% · Reported 2026-03-31
iShares Core S&P Mid-Cap ETF7,422,263 shares · 3.18% · Reported 2026-08-31

View more holders (8)

Vanguard MStar Total Stk Mkt Idx Invest6,737,215 shares · 2.89% · Reported 2026-07-31
iShares Russell 2000 ETF5,498,189 shares · 2.36% · Reported 2026-08-31
JPMorgan Chase & Co5,240,816 shares · 2.25% · Reported 2026-03-31
Geode Capital Management, LLC5,198,779 shares · 2.23% · Reported 2026-03-31
Vanguard Small Cap Index4,873,115 shares · 2.09% · Reported 2026-07-31
Bank of America Corp4,357,672 shares · 1.87% · Reported 2026-03-31
UBS Group AG4,151,638 shares · 1.78% · Reported 2026-03-31
Vanguard MStar Small Cap Growth Indx Inv2,820,466 shares · 1.21% · Reported 2026-07-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company's financial health is showing major warning signs after a period of rapid growth. While 2025 was highly profitable with strong revenue growth, the first quarter of 2026 revealed a severe reversal, with growth slowing to single digits and the company posting a massive net loss of ninety-two million dollars. Most assessments agree that the highly profitable days of selling custom weight-loss drugs are ending, and the shift to selling lower-margin brand-name drugs will permanently hurt earnings. However, there is disagreement on the future outlook. Some believe the company can recover its profitability by 2028 as it scales its new business, while others argue that the earnings power is structurally broken and the company will continue to burn cash due to high customer acquisition costs.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

Profit margins are facing a structural collapse. Historically, the company enjoyed exceptionally high gross margins of around eighty percent by selling custom-compounded drugs. However, have plummeted to sixty-five percent and operating margins have swung deep into the red. Most assessments agree that this margin compression is permanent, driven by the forced transition to reselling lower-margin brand-name drugs and skyrocketing customer acquisition costs. Opinions clash on the future trajectory. Bullish views suggest that margins will stabilize and eventually expand as marketing costs normalize and automated systems take over. Bearish views argue that without a unique product, the company will be forced to compete on price against massive retail giants, permanently dragging margins down to traditional retail pharmacy levels and destroying the justification for its high valuation.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2018-12-31	26,679,000	-57,330,000	-75,243,000	29.25	-284	-282.03	-214.89
2019-12-31	82,558,000	-76,654,000	-72,064,000	54.03	-90.14	-87.29	-92.85
2020-12-31	148,757,000	-6,712,000	-18,114,000	73.58	-10.18	-12.18	-4.51
2021-12-31	271,878,000	-39,419,000	-107,659,000	75.22	-42.31	-39.6	-14.5
2022-12-31	526,916,000	-33,778,000	-65,678,000	77.57	-13.04	-12.46	-6.41
2023-12-31	872,000,000	46,991,000	-23,546,000	81.99	-3.38	-2.7	5.39
2024-12-31	1,476,514,000	198,334,000	126,038,000	79.45	4.19	8.54	13.43
2025-12-31	2,347,637,000	73,961,000	128,365,000	73.84	4.5	5.47	3.15

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	62.76	Trailing four quarters
2024-12-31	46.18	Trailing four quarters

Shares outstanding — chart values
Reporting date	Shares outstanding
2019-01-01	39,089,600
2020-01-01	79,311,900
2021-01-01	201,363,300
2022-01-01	206,140,300
2023-01-01	209,739,700
2024-01-01	240,725,400
2025-01-01	248,096,400
2026-01-01	231,746,100

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.